• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Teva Pharmaceutical Industries (TEVA) Starts Direct NYSE Share Trading In Shift From ADS

    Simply Wall St·09/16/2026 03:34:23
    Listen to the news
    • Teva Pharmaceutical Industries (NYSE:TEVA) began direct trading of its ordinary shares on the New York Stock Exchange, replacing its prior American Depositary Shares program.
    • The move reshapes Teva's U.S. capital markets presence by aligning its primary share class with global investors on a single major venue.
    • Management has linked the NYSE ordinary share listing to the firm's Pivot to Growth plan, which includes new product launches and the use of AI to improve efficiency.
    • Teva's shift to direct ordinary share trading on the NYSE sits alongside broader shifts in its strategy and risk profile our research tracks. We have also spotted 2 warning signs (1 major) worth knowing about at Teva Pharmaceutical Industries.

    For readers looking beyond Teva Pharmaceutical Industries to more ideas in this corner of the market, start with 19 top founder-led companies.

    NYSE:TEVA 1-Year Stock Price Chart
    NYSE:TEVA 1-Year Stock Price Chart

    Teva Pharmaceutical Industries operates as a large US-based pharmaceuticals group with a focus on generic medicines and biopharmaceutical products across the United States, Europe, Israel, and other markets, so its NYSE ordinary share listing ties directly to a broad, globally diversified commercial footprint.

    See which insiders are buying and selling Teva Pharmaceutical Industries following this latest news.

    What Teva’s NYSE ordinary share move really signals about the growth story

    The Teva Pharmaceutical Industries Narrative rests on a simple bet. The business is trying to shift investor focus from its leveraged past and flat generics base to a higher margin mix of branded drugs, biosimilars, and specialty assets, and this NYSE ordinary share listing is meant to make that story easier to own at scale.

    "Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix...

    See how the full story points towards a $41.91 fair value for Teva Pharmaceutical Industries.

    For the bull Narrative, shifting from American Depositary Shares to ordinary shares on the NYSE lines up with the Pivot to Growth pitch. It simplifies access for large global investors who want direct exposure to TEV ‘408, ecopipam and the branded portfolio that analysts already frame as the key earnings driver versus a muted generics base.

    The bear reading is that greater accessibility also means a wider audience scrutinising Teva’s heavy debt load and concentration in a few branded drugs, similar to how investors treat specialty players like Viatris or Viiv’s partners. If execution on celiac, vitiligo and Tourette’s timelines slips, the same ordinary share structure could make sentiment swing faster when expectations reset.

    The ordinary share listing therefore reads as either a cleaner gateway into Teva’s growth tilt or a more liquid venue for sceptics, depending on which Narrative you think best fits the evidence so far.

    The big unanswered question at Teva Pharmaceutical Industries

    Everything here has focused on products, balance sheet and listing mechanics, but the real steering wheel is who runs Teva Pharmaceutical Industries and how their rewards are structured for doing it. See who is actually steering Teva Pharmaceutical Industries, and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.